What is Leerink Partnrs’ Estimate for Nkarta Q1 Earnings?

Nkarta, Inc. (NASDAQ:NKTX) – Equities researchers at Leerink Partnrs issued their Q1 2026 earnings per share estimates for Nkarta in a research report issued on Tuesday, November 11th. Leerink Partnrs analyst D. Graybosch anticipates that the company will post earnings of ($0.37) per share for the quarter. The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Nkarta’s Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.45) EPS and Q4 2026 earnings at ($0.45) EPS.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03.

Other research analysts have also recently issued research reports about the company. Wall Street Zen raised Nkarta from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. Stifel Nicolaus lowered their price objective on Nkarta from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Nkarta in a report on Friday, October 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price target on shares of Nkarta in a report on Wednesday, August 13th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $13.25.

Nkarta Stock Performance

Shares of Nkarta stock opened at $2.01 on Wednesday. The stock has a 50 day moving average price of $2.14 and a two-hundred day moving average price of $2.01. Nkarta has a 52 week low of $1.31 and a 52 week high of $3.40. The stock has a market capitalization of $142.77 million, a PE ratio of -1.46 and a beta of 0.86.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in NKTX. Peapod Lane Capital LLC boosted its position in shares of Nkarta by 1.1% during the third quarter. Peapod Lane Capital LLC now owns 671,266 shares of the company’s stock valued at $1,390,000 after purchasing an additional 7,416 shares in the last quarter. Monaco Asset Management SAM boosted its holdings in shares of Nkarta by 24.5% during the 3rd quarter. Monaco Asset Management SAM now owns 1,970,910 shares of the company’s stock valued at $4,080,000 after buying an additional 387,538 shares in the last quarter. Bailard Inc. bought a new stake in shares of Nkarta during the 3rd quarter valued at $61,000. SG Americas Securities LLC grew its position in shares of Nkarta by 35.0% in the 3rd quarter. SG Americas Securities LLC now owns 23,663 shares of the company’s stock worth $49,000 after buying an additional 6,141 shares during the period. Finally, Forefront Wealth Partners LLC bought a new position in shares of Nkarta in the 3rd quarter worth about $82,000. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.